Growing Human Heart Valve Tissue From Stem Cells Creates an Experimental Platform for Rheumatic Heart Disease

Heart valves may look like little more than a few thin pieces of tissue, but they must withstand the repeated impact of blood flow throughout a lifetime. When valves are damaged by congenital defects or rheumatic heart disease, the challenge is especially difficult for children: existing artificial valves do not grow with the body, often meaning additional surgery later. A team at the Murdoch Children’s Research Institute in Melbourne, Australia, has now grown valve-like tissue from human pluripotent stem cells, initially addressing the long-standing lack of suitable human experimental models.

The study, published in *Cell Stem Cell*, shows that the team first directed pluripotent stem cells to differentiate into valvular interstitial cells, then allowed the cells to self-organize into three-dimensional tissue rich in extracellular matrix. Early conference data showed that single-cell RNA sequencing identified interstitial and immune cell identities resembling those in native valves; proteomic analysis detected 98% of the proteins found in native valves in the engineered tissue. These results support the model’s similarity in molecular composition, but do not mean it has the shape, blood-flow control capabilities, or clinical durability of a complete valve.

One immediate use of the platform is to study rheumatic heart disease. The disease typically begins with a dysregulated immune response following group A streptococcal infection, with repeated inflammation and scarring progressively damaging the valves. Because the infection and immune response are distinctly human-specific, conventional animal models struggle to fully reproduce the course of the disease. The research team has used the cultured tissue to model related inflammatory changes, and subsequent plans include separately testing cytokines, group A Streptococcus-associated autoantibodies, and immune cells to clarify how they drive valve damage.

If the model can reliably reproduce the responses of patient tissue, it could serve as an intermediary platform for comparing candidate drugs and identifying repair mechanisms, and might reduce the reliance of some early-stage research on animal models. However, currently available data do not show that it has completed large-scale drug screening, nor is there evidence that efficacy signals in the model can predict patients’ clinical responses. Whether patient serum, different stem cell lines, and different culture batches produce consistent results remains a question that must be answered as the disease model moves toward practical use.

Another avenue of the research is to advance these cellular materials toward a true living valve. The team has conducted mechanical testing, including uniaxial tensile tests. Early subcutaneous implantation experiments showed no calcification, and mechanical stimulation is also being used to improve the tissue’s strength and elasticity. However, subcutaneous implantation is entirely different from placement in a beating heart, where the tissue must withstand high-pressure blood flow over the long term. The engineered tissue must still demonstrate that it can form valve leaflets that open and close, withstand fatigue loading, and safely integrate in the body without causing thrombosis, immune reactions, or abnormal proliferation.

Accordingly, the most mature positioning of this achievement is not as a “lab-grown heart valve” ready for immediate transplantation, but as a research tool that more closely reflects human valve biology. It brings disease mechanisms, drug testing, and regenerative medicine together on a single tissue platform. Whether it can ultimately be developed into a personalized valve that grows with a child and eliminates multiple replacement surgeries will still require extensive validation, including culture under dynamic blood flow, long-term studies in large animals, manufacturing consistency, and clinical safety assessments.